How the body biotransforms the drug, primarily via cytochrome P450 (CYP) enzymes in the liver.
The process begins by identifying a biological macromolecule—typically a receptor, enzyme, ion channel, or nucleic acid—whose activity is directly tied to a specific disease state. Pharmacologists use advanced genetic tools (such as CRISPR-Cas9), RNA interference, and disease-specific cell assays to confirm that modulating this target will yield a therapeutic response. Target validation requires proving that the target is "druggable," meaning its physical structure contains distinct binding pockets capable of interacting with chemical or biological entities. 2. High-Throughput Screening (HTS) and Hit Identification pharmacology in drug discovery and development
The cornerstone of preclinical and clinical pharmacology is the optimization of the PK/PD relationship. This dynamic framework predicts how a drug behaves inside a living system and directly informs the design of human dosing regimens. Pharmacokinetics: The ADME Paradigm How the body biotransforms the drug, primarily via